Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (Diluted Average): 2009-2022

Historic Shares Outstanding (Diluted Average) for Gyre Therapeutics (GYRE) over the last 5 years, with Dec 2022 value amounting to $31.5 million.

  • Gyre Therapeutics' Shares Outstanding (Diluted Average) rose 20.16% to $38.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $38.0 million, marking a year-over-year increase of 20.16%. This contributed to the annual value of $31.5 million for FY2022, which is 2.95% up from last year.
  • Gyre Therapeutics' Shares Outstanding (Diluted Average) amounted to $31.5 million in FY2022, which was up 2.95% from $30.6 million recorded in FY2021.
  • Gyre Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $31.5 million for FY2022, and its period low was $30.6 million during FY2021.
  • Over the past 2 years, Gyre Therapeutics' median Shares Outstanding (Diluted Average) value was $31.1 million (recorded in 2021), while the average stood at $31.1 million.
  • Data for Gyre Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY climbed of 2.95% (in 2022) over the last 5 years.
  • Over the past 2 years, Gyre Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $30.6 million in 2021, then climbed by 2.95% to $31.5 million in 2022.